Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient

Lauren M. Czosnowski, Joanna Laizure, Robert B. Canada

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Secondary hyperparathyroidism and the associated metabolic abnormalities are common complications of chronic kidney disease. When these disorders cannot be managed by conventional measures, including phosphate restriction, phosphate binders, vitamin D therapy, and calcimimetics, tertiary hyperparathyroidism and the associated metabolic abnormalities may develop. In such cases parathyroidectomy is required. We report a case in which a patient with tertiary hyperparathyroidism and refractory hypercalcemia who was not a surgical candidate was managed with the bisphosphonate pamidronate. This patient had failed conventional measures to manage hypercalcemia and presented with mental status changes. Pamidronate therapy was associated with a sustained decrease in serum calcium concentration and improvement in clinical symptoms. This is the first case, to our knowledge, in which pamidronate was used in a patient refractory to all other reasonable medical management, including calcimimetics.

Original languageEnglish (US)
Pages (from-to)300-301
Number of pages2
JournalAmerican Journal of the Medical Sciences
Volume337
Issue number4
DOIs
StatePublished - Jan 1 2009

Fingerprint

pamidronate
Hyperparathyroidism
Hypercalcemia
Renal Dialysis
Phosphates
Parathyroidectomy
Secondary Hyperparathyroidism
Diphosphonates
Chronic Renal Insufficiency
Vitamin D
Calcium
Therapeutics
Serum

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient. / Czosnowski, Lauren M.; Laizure, Joanna; Canada, Robert B.

In: American Journal of the Medical Sciences, Vol. 337, No. 4, 01.01.2009, p. 300-301.

Research output: Contribution to journalArticle

@article{4cf0a4b1923b49d5a35ff3a76fdb9d85,
title = "Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient",
abstract = "Secondary hyperparathyroidism and the associated metabolic abnormalities are common complications of chronic kidney disease. When these disorders cannot be managed by conventional measures, including phosphate restriction, phosphate binders, vitamin D therapy, and calcimimetics, tertiary hyperparathyroidism and the associated metabolic abnormalities may develop. In such cases parathyroidectomy is required. We report a case in which a patient with tertiary hyperparathyroidism and refractory hypercalcemia who was not a surgical candidate was managed with the bisphosphonate pamidronate. This patient had failed conventional measures to manage hypercalcemia and presented with mental status changes. Pamidronate therapy was associated with a sustained decrease in serum calcium concentration and improvement in clinical symptoms. This is the first case, to our knowledge, in which pamidronate was used in a patient refractory to all other reasonable medical management, including calcimimetics.",
author = "Czosnowski, {Lauren M.} and Joanna Laizure and Canada, {Robert B.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1097/MAJ.0b013e31818a84a5",
language = "English (US)",
volume = "337",
pages = "300--301",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient

AU - Czosnowski, Lauren M.

AU - Laizure, Joanna

AU - Canada, Robert B.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Secondary hyperparathyroidism and the associated metabolic abnormalities are common complications of chronic kidney disease. When these disorders cannot be managed by conventional measures, including phosphate restriction, phosphate binders, vitamin D therapy, and calcimimetics, tertiary hyperparathyroidism and the associated metabolic abnormalities may develop. In such cases parathyroidectomy is required. We report a case in which a patient with tertiary hyperparathyroidism and refractory hypercalcemia who was not a surgical candidate was managed with the bisphosphonate pamidronate. This patient had failed conventional measures to manage hypercalcemia and presented with mental status changes. Pamidronate therapy was associated with a sustained decrease in serum calcium concentration and improvement in clinical symptoms. This is the first case, to our knowledge, in which pamidronate was used in a patient refractory to all other reasonable medical management, including calcimimetics.

AB - Secondary hyperparathyroidism and the associated metabolic abnormalities are common complications of chronic kidney disease. When these disorders cannot be managed by conventional measures, including phosphate restriction, phosphate binders, vitamin D therapy, and calcimimetics, tertiary hyperparathyroidism and the associated metabolic abnormalities may develop. In such cases parathyroidectomy is required. We report a case in which a patient with tertiary hyperparathyroidism and refractory hypercalcemia who was not a surgical candidate was managed with the bisphosphonate pamidronate. This patient had failed conventional measures to manage hypercalcemia and presented with mental status changes. Pamidronate therapy was associated with a sustained decrease in serum calcium concentration and improvement in clinical symptoms. This is the first case, to our knowledge, in which pamidronate was used in a patient refractory to all other reasonable medical management, including calcimimetics.

UR - http://www.scopus.com/inward/record.url?scp=65549085314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549085314&partnerID=8YFLogxK

U2 - 10.1097/MAJ.0b013e31818a84a5

DO - 10.1097/MAJ.0b013e31818a84a5

M3 - Article

VL - 337

SP - 300

EP - 301

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 4

ER -